<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01321164</url>
  </required_header>
  <id_info>
    <org_study_id>FPUVB 005</org_study_id>
    <nct_id>NCT01321164</nct_id>
  </id_info>
  <brief_title>Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis</brief_title>
  <official_title>Fumaric Acid Esters Versus Fumaric Acid Esters Plus Narrow Band Type B Ultraviolet (UVB) in Patients With Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to evaluate the additional effect of a narrow band Type B
      Ultraviolet (UVB) therapy on the treatment of severe plaque psoriasis with fumaric acid
      esters (FAE) in comparison to FAE monotherapy. The secondary objectives are to evaluate the
      effect of an additional narrow band UVB therapy on the cumulative FAE dose required to reach
      Psoriasis Area and Severity Index (PASI) 75 in comparison to FAE monotherapy and to evaluate
      whether a leukopenia and lymphopenia frequently occurring during the FAE treatment is a
      positive predictive factor for the treatment response.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean reduction in Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean cumulative FAE dose required to reach PASI 75</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean reduction in Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean reduction in Psoriasis Log-based Area and Severity Index (PLASI)</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean reduction in Dermatology Life Quality INDEX (DLQI)</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean white blood cells (Leukocytes and Lymphocytes) count</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Correlation between the mean white blood cells (Leukocytes and Lymphocytes) count and PASI reduction and between the mean white blood cells count and cumulative FAE dose.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Fumaric acid esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fumaric acid esters monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fumaric acid esters plus narrow band UVB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy of fumaric acid esters plus narrow band type B ultraviolet therapy (UVB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Full Body UV Therapy System UV 7002 plus fumaric acid esters</intervention_name>
    <description>Combination therapy of narrow band type B ultraviolet (UVB) therapy plus fumaric acid esters therapy.
Narrow band UVB therapy: 3 times a week for 6 weeks; Fumaric acid esters therapy: Capsules, schema therapy, 1 to 3 times a day for 6 months</description>
    <arm_group_label>fumaric acid esters plus narrow band UVB</arm_group_label>
    <other_name>TL-01;</other_name>
    <other_name>Irradiation therapy with narrow band UVB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fumaric acid esters</intervention_name>
    <description>Monotherapy, Capsules, schema therapy, 1 to 3 times a day, 6 months</description>
    <arm_group_label>Fumaric acid esters</arm_group_label>
    <other_name>Fumaric acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with moderately severe to severe Psoriasis (BSA ≥ 10 and PASI ≥ 10)

          -  Age between 18 and 80 years old

        Exclusion Criteria:

          -  pregnant woman and satisfying women

          -  cancer, chronic infections, autoimmune diseases

          -  gastrointestinal illnesses

          -  liver diseases

          -  renal malfunctions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Tanew, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Department of Dermatology, Division of General Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna; Department of Dermatology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2011</study_first_submitted>
  <study_first_submitted_qc>March 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2011</study_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Adrian Tanew</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

